Clinical Trials Logo

Filter by:
NCT ID: NCT04511442 Completed - Obesity Clinical Trials

Study of Food Preferences and Sensory Perceptions After Bariatric Surgery

BariaTaste 2
Start date: April 26, 2021
Phase:
Study type: Observational

Several studies report changes in food preferences in favor of low energy density foods after bariatric surgery and changes in scores of liking and desire to eat, as well as changes in hedonic evaluation certain foods. However, only one study was held in a more realistic condition of consumption by using real food, looking at some aspects of food preferences and giving contradictory results. We hypothesise that food preferences are different between obese people with and without a bariatric surgery. The main objective of this study is to compare the differences in food quality (proportion of total energy intake from foods with high energy density versus foods with low energy density), evaluated during a standardized and validated buffet between adult women with severe complicated or morbid obesity and women who have undergone bariatric surgery in the last 12 months.

NCT ID: NCT04510467 Terminated - Covid19 Clinical Trials

Mental Health Consequences of COVID19 Infection in the French RMD Cohort

MentCovid19RMD
Start date: January 20, 2021
Phase:
Study type: Observational

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

NCT ID: NCT04510454 Completed - Cancer Clinical Trials

Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19

ONCOVID-21
Start date: November 2, 2020
Phase: N/A
Study type: Interventional

Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test).

NCT ID: NCT04510350 Completed - Multiple Sclerosis Clinical Trials

Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

CISCO
Start date: February 19, 2020
Phase:
Study type: Observational

The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.

NCT ID: NCT04509700 Recruiting - B-Cell Malignancies Clinical Trials

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Start date: August 3, 2020
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

NCT ID: NCT04509674 Completed - Clinical trials for Myocardial Infarction

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Start date: December 16, 2020
Phase: Phase 3
Study type: Interventional

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease. People who are in hospital may join the study soon after being treated for their heart attack. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. All participants continue their standard treatment. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. Empagliflozin is a medicine that helps people with type 2 diabetes to lower their blood sugar. Researchers think that empagliflozin might also help people after heart attack who are at risk for heart failure, whether or not they have diabetes. Participants are in the study for about 1 to 2 years. During this time, there are about 4 visits inperson, 2 visits are done either by phone or by use of an mobile application. Results between the empagliflozin and placebo groups are compared. The doctors also regularly check the general health of the participants.

NCT ID: NCT04508673 Completed - Clinical trials for Growth Hormone Deficiency

Impact of GH Measurements on GHD Diagnosis

Start date: April 1, 2019
Phase:
Study type: Observational

Human growth hormone (hGH) provocation test is an essential tool to assess growth hormone deficiency in children and young adults. It is important to have a robust and reliable method to determine the hGH peak of stimulation. This work aimed to compare three common automated immunoassays for hGH measurements and to assess whether there are still result-related differences influencing clinical decision.

NCT ID: NCT04508231 Active, not recruiting - Gender Dysphoria Clinical Trials

Metabolic Consequences of Cross-sex Hormonal Treatment

DysGeMet
Start date: July 24, 2020
Phase:
Study type: Observational

Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls

NCT ID: NCT04507113 Recruiting - Clinical trials for Magnetic Resonance Imaging

Diffusion Tensor (DTI) for the Assessement of Therapeutic Evolution of Patients With Acute Lumbar Radiculalgia

DiTi-Aïe
Start date: April 6, 2022
Phase: N/A
Study type: Interventional

Diffusion tensor imaging (DTI) is a non-invasive MRI technique offering a functional approach that provides morphological information about the microstructures of the nerve roots. DTI is a widely used neuroimaging technique and is a current topic of research in the field of peripheral nerve imaging.The aim of the study is to determine the prognostic quality of the DTI parameters to predict the therapeutic evolution of patients with lumbar radiculalgia at 6 months.

NCT ID: NCT04506866 Terminated - Overactive Bladder Clinical Trials

InterStim Micro Post Market Clinical Follow-up Study

ELITE
Start date: August 25, 2020
Phase: N/A
Study type: Interventional

Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.